Search

The term «rhinitis» comprises a large heterogeneous group of diseases with different etiology and pathophysiological mechanisms. The latest consensual documents recommend that all rhinitis be classified into 3 main types: infectious, allergic (AR) and non-infectious and non-allergic with subsequent subdivision of each type into separate subtypes. In the Russian Federation, standards and clinical guidelines have been developed only for allergic rhinitis. The therapeutic agement of 779 patients with chronic rhinitis in outpatient settings have been analysed. When formulating the diagnosis, codes J31.0 and J30.0 and the terms «Hypertrophic rhinitis» and «Vasomotor rhinitis» were used for non-allergic rhinitis, while code J30.4 and the terms «Allergic rhinitis» or «Vasomotor-allergic rhinitis» were used for allergic genesis. The diagnosis «Intermittent AR» was indicated once, and severity was mentioned only in 2 patients. In AR group (216 people), a comprehensive study was performed in 6.5% of cases, the diagnosis was established empirically in 52.7% of cases. Antihistamines were prescribed in 27.3% of cases, intranasal corticosteroids in 77.8%, montelukast in 9.7%, allergen-specific immunotherapy was performed in 1.9%. In non-allergic rhinitis (563 patients), 77.4% intranasal received corticosteroids, 7.5% received antihistamines, 3.7% – montelukast, 4.8% underwent surgical treatment. In both groups, original methods of therapy in the form of local antibiotics, homeopathic drugs, bacterial lysates were reported. In the AR group, a violation of the step-by-step therapy regimen was identified.

The issue of diagnostics and therapy of chronic tonsillitis remains the most difficult and urgent in otorhinolaryngology. Detection of titers to streptolysin Beta-hemolytic streptococcus when determining the therapeutic tactics and management of patients with chronic tonsillitis is a sufficiently frequent diagnostic criterion in the RF. When analyzing the literature data and results of own studies a dubious value of Antistreptolysin O for determination of the degree of the inflammatory process degree in palatine tonsils and making up a plan of therapeutic measures based on this value was identified.

"Teaching and Research Medical Center" Federal State Institution of the Russian Federation Presidential Administration ARVI is a very widespread disease that requires a comprehensive approach to treatment, should be targeted at relieving clinical symptoms and meet current safety requirements to medicines. The market of combination drugs for the treatment of ARVI is represented by a variety of drugs for the symptomatic and pathogenetic therapy. AnviMax is the only drug with additional etiotropic action against viral agent which contains antiviral component rimantadine.

Allergic rhinitis is one of the most common chronic diseases, affecting from 20 to 30% of adult population and 40% of children [8, 19]. In the past decades, the incidence of allergic rhinitis has been growing all over the world. 9% of the European population and 8.8 -16% of the U.S. population suffer from the pathology [1, 4]. Widespread comorbid conditions of allergic rhinitis which exacerbate the clinical pattern are asthma, sinusitis, otitis media [20, 24]. The disease is characterized by symptoms of different intensity which deteriorate the quality of life, everyday activity and productivity, even when treatment is quite effective [3, 14]. The main criteria in diagnosis of allergic rhinitis are medical history, clinical manifestations, positive skin tests and allergen-specific antibodies in blood serum.

Persistent (year-round) allergic rhinitis is one of the most pressing global health problems characterized by a steady growth in the number of patients in every country, including Russia. The disease has a dramatic impact on the quality of life, while the economic cost of the fight against allergic rhinitis and its complications is a significant financial burden. Topical corticosteroids are the treatment of choice in patients with persistent allergic rhinitis.